Biocon Limited secures Pebrilzo launches and USD 400m Brazil deal

Biocon Limited secured the earliest licensed Pebrilzo launch dates across the European Union, United Kingdom, United States and other markets, alongside a 10-year Brazilian Pertuzumab partnership valued at approximately USD 400 million in Q2FY27 ended September 30, 2026. The Genentech settlement and Brazil PDP define commercial pathways for the biosimilar oncology product.

What did Biocon announce for Pebrilzo?

Biocon announced a global patent settlement with Genentech that secures the earliest licensed launch dates for Pebrilzo across the European Union, United Kingdom, United States and other Rest of the World countries. Pebrilzo is Biocon's biosimilar Pertuzumab, and the November 4, 2026 filing does not disclose individual launch dates, settlement payments or product volumes.

Management said the settlement provides greater visibility to a significant future growth driver. Shreehas Tambe, Biocon's chief executive officer and managing director, identified an upcoming European Pertuzumab launch as part of the company's second-half FY27 plans, but did not provide a launch date or revenue forecast.

Biocon also received a positive opinion for its biosimilar Pertuzumab from the European Medicines Agency's Committee for Medicinal Products for Human Use. The company said Pertuzumab was the first monoclonal antibody biosimilar recommended under the European Medicines Agency's tailored clinical development approach, while Executive Chairperson Kiran Mazumdar-Shaw described the decision as a milestone for biosimilar innovation and patient access.

What does Biocon's Brazil Pertuzumab partnership cover?

Biocon secured a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at approximately USD 400 million. The agreement is intended to support long-term adoption through Brazil's public oncology network, making it a disclosed public-sector commercial arrangement for the Pertuzumab product.

The filing gives the partnership's duration and approximate value but does not specify annual revenue recognition, delivery milestones, product volumes or payment timing. The approximately USD 400 million figure is therefore the disclosed value of the 10-year arrangement, not Q2FY27 revenue.

Brazil formed part of wider emerging-market activity during Q2FY27. Across Asia-Pacific, Latin America, Africa, the Middle East, Turkey and the Commonwealth of Independent States, Biocon executed 13 product launches and secured 13 regulatory approvals across multiple therapeutic areas; the Brazil agreement is specifically for Pertuzumab and public oncology access.

How did Biocon's biosimilars business perform in Q2FY27?

Biocon's biosimilars revenue rose 3% year on year to Rs 2,809 crore in Q2FY27 from Rs 2,721 crore in Q2FY26. Generics revenue increased 10% to Rs 774 crore, taking biopharma revenue, which combines biosimilars and generics, up 5% to Rs 3,583 crore.

Biosimilars produced the larger absolute revenue increase, rising by Rs 88 crore, compared with the Rs 73 crore increase in generics. In H1FY27, biosimilars revenue grew 9% to Rs 5,664 crore from Rs 5,179 crore, while total biopharma revenue rose 11% to Rs 7,200 crore from Rs 6,511 crore.

In North America, Biocon said Yesintek, its biosimilar Ustekinumab, continued to gain market share in the United States. The company also commercialised Yesafili, or aflibercept-jbvf, as an interchangeable biosimilar Aflibercept in the United States and secured approvals for the Yesintek autoinjector in the United States and Canada, without disclosing product-level sales or market-share figures.

What were Biocon's Q2FY27 financial results?

Biocon reported consolidated revenue from operations of Rs 4,389 crore in Q2FY27, up 2% from Rs 4,296 crore a year earlier, while total income increased 1% to Rs 4,423 crore. Other income fell 63% to Rs 34 crore from Rs 93 crore, limiting total-income growth relative to operating revenue.

Earnings before interest, tax, depreciation and amortisation, or EBITDA, declined 7% to Rs 865 crore and the EBITDA margin was 20%, compared with 22% in Q2FY26. Reported net profit fell 52% to Rs 41 crore from Rs 85 crore, while interest and finance charges decreased 12% to Rs 240 crore after actions to strengthen the balance sheet.

Services revenue declined 9% year on year to Rs 833 crore in Q2FY27, although Biocon said it grew 13% sequentially. Syngene, the services business, attributed the year-on-year revenue decline to lower Zoetis revenue and foreign-exchange hedge losses, and reported an operating EBITDA margin of 18%.

What operational developments could support Biocon's plans?

Biocon said its second Insulin Glargine drug-product fill-finish line in Malaysia became operational, with commercial supplies already under way. The line has approvals from the United Kingdom's Medicines and Healthcare products Regulatory Agency and the European Medicines Agency, and management said the capacity is intended to support growing United States demand.

In the United States, Biocon secured more than USD 100 million in new contracts and major payor wins for commercialised products, alongside strong demand for Insulin Glargine. The filing does not identify the products covered by those contracts or state how much of the value could be recognised in FY27.

Biocon also commercialised biosimilar Ustekinumab autoinjector, Denosumab and Aflibercept across several European markets. Those products address immunology, bone health and ophthalmology, respectively, while Pertuzumab is the oncology product linked to the upcoming European launch and the 10-year Brazil PDP.

Conclusion

Biocon's Genentech settlement and approximately USD 400 million Brazil PDP establish disclosed launch and adoption routes for Pebrilzo in developed and emerging markets. The agreements arrived as biosimilars revenue rose 3% year on year to Rs 2,809 crore in Q2FY27, while reported net profit declined 52% to Rs 41 crore and EBITDA margin was 20%.

The next disclosed event to watch is the upcoming European Pertuzumab launch, which management linked to its second-half FY27 plans. Further updates on licensed launch dates, Brazil partnership revenue timing and the more than USD 100 million of United States contracts would clarify the commercial pace of Biocon's biosimilar programme.